JPRN-UMIN000007976已完成未知
Japan-Based clinical ReseArch Network for Diabetes Registry - J-BRAND Registry
J-BRAND Registry Study Group0 个研究点目标入组 5,208 人开始时间: 2012年5月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5,208
研究概览
简要总结
The same level of safety and efficacy was shown between groups A and B, confirming the usefulness of alogliptin for the treatment of type 2 diabetes
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Any subject who meets any of the following criteria will not qualify for entry into the study: (1)Patients using parenteral hypoglycemic agents (insulin and glucagon-like peptide-1 [GLP-1] receptor agonists) (2)Patients with severe ketosis, diabetic coma or precoma, severe infection, or serious trauma and patients under the perioperative management (3)Pregnant or lactating women (4)Patients judged by the principal investigator or sub-investigator to be ineligible for participation as study subjects for any other reason
研究者
相似试验
已完成
不适用
To Evaluate Clinical Efficacy and Safety of Diabetes-Specific Formula (Nutren Diabetes)Diabetes MellitusNCT05859165Société des Produits Nestlé (SPN)233
已完成
3 期
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular ComplicationsDiabetes Mellitus, Type 2NCT00097786Novartis Pharmaceuticals9,306
已完成
不适用
Japan Diabetes Outcome Intervention Trial 2 (J-DOIT2) The large trial to improve the medical care of the family doctors for type 2 diabetes patients and to decrease dropout rate of these patients.Type 2 Diabetes MellitusJPRN-UMIN000002186Japan Foundation for the Promotion of International Medical Research Cooperation3,750
已完成
不适用
Japan Diabetes Outcome Intervention Trial 2 (J-DOIT2) Pilot research about efficiency of a system supporting type 2 diabetes mellitus medical care by a family doctorType 2 Diabetes MellitusJPRN-UMIN000000481Japan Foundation for the Promotion of International Medical Research Cooperation2,400
已完成
3 期
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01059799Novo Nordisk A/S435